The effect of high-flux hemodialysis on dialysis-associated amyloidosis

被引:33
作者
Ayli, M [2 ]
Ayli, D
Azak, A
Yüksel, C
Atilgan, G
Dede, F
Akalin, T
Abayli, E
Çamlibel, M
Ayli, M [2 ]
Ayli, D
Azak, A
机构
[1] Ankara Numune Training & Res Hosp, Dept Nephrol, Ankara, Turkey
[2] Ankara Numune Egitim Arastirma Hastanesi, Ankara, Turkey
[3] Yasam Dialysis Ctr, Ankara, Turkey
关键词
high-flux; hemodialysis; amyloidosis; beta-2; microglobulin;
D O I
10.1081/JDI-200042868
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Amyloidosis is an important cause of mortality and morbidity in patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD). In this study, depending on the idea that the clearance of middle and high molecular weight toxins could be improved, we aimed to investigate the effect of high-flux dialyzer on clearance of beta-2 microglobulin (beta2-MG) and calcium (Ca) phosphorus (P) metabolism in patients under HD treatment. Forty-eight patients with ESRD under chronic HD treatment were included in the study. All patients were randomized into two groups, and HD was performed with low-flux or high-flux dialyzer for 6 months. In the high-flux group, the reduction of beta2-MG and P levels during dialysis was significantly higher when compared with the low-flux group (p < 0.001). During the follow-up period, while beta2-MG levels decreased significantly in the high-flux group (p < 0.05), there was an increase in the low-flux group (p < 0.05). As a result, our findings suggest that use of high-flux dialyzer can be an efficient alternative in terms of controlling the clearance of beta2-MG and impaired Ca and P metabolism. These beneficial effects of high-flux dialyzers are probably mediated by the improved clearance of middle and high molecular weight toxins.
引用
收藏
页码:31 / 34
页数:4
相关论文
共 14 条
[1]  
Brancaccio D, 2002, J NEPHROL, V15, pS86
[2]  
Eknoyan G, 1997, KIDNEY INT, V52, P1395
[3]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[4]   High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis [J].
Kiichle, C ;
Fricke, H ;
Held, E ;
Schiffl, H .
AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (06) :484-488
[5]   Programmed filtration, a new method for removing large molecules and regulating albumin leakage during hemodiafiltration treatment [J].
Kim, ST ;
Yamamoto, C ;
Taoka, M ;
Takasugi, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) :S220-S223
[6]   DIALYSIS-RELATED AMYLOIDOSIS [J].
KOCH, KM ;
GENNARI, FJ ;
VANYPERSELE, C ;
REES, A ;
GOLDMAN, M ;
MIHATSCH, MJ ;
MION, CM ;
BORSATTI, A ;
WINEARLS, CG ;
DAVISON, AM ;
COHEN, JJ ;
MADIAS, NE ;
OLMER, M ;
HARRINGTON, JT ;
BAGGIO, B ;
RAMBAUSEK, MH ;
DONOHOE, JF ;
VANES, LA .
KIDNEY INTERNATIONAL, 1992, 41 (05) :1416-1429
[7]   Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients [J].
Koda, Y ;
Nishi, S ;
Miyazaki, S ;
Haginoshita, S ;
Sakurabayashi, T ;
Suzuki, M ;
Sakai, S ;
Yuasa, Y ;
Hirasawa, Y ;
Nishi, T .
KIDNEY INTERNATIONAL, 1997, 52 (04) :1096-1101
[8]   Effect of high-flux dialysis on the anaemia of haemodialysis patients [J].
Locatelli, F ;
Andrulli, S ;
Pecchini, F ;
Pedrini, T ;
Agliata, S ;
Lucchi, L ;
Farina, M ;
La Milia, V ;
Grassi, C ;
Borghi, M ;
Redaelli, B ;
Conte, F ;
Ratto, G ;
Cabiddu, G ;
Grossi, C ;
Modenese, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (09) :1399-1409
[9]   Management of secondary hyperparathyroidism:: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product [J].
Moe, SM ;
Drüeke, TB .
AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (06) :369-379
[10]   Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux [J].
Schiffl, H ;
Fischer, R ;
Lang, SM ;
Mangel, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (06) :840-845